Study the effect of formulation variables on drug release from hydrophilic matrix tablets of milnacipran and prediction of in-vivo plasma profile.
The objective of this study was to design oral controlled release (CR) matrix tablets of Milnacipran using hydroxypropyl methylcellulose (HPMC) as the retardant polymer and to study the effect of various formulation factors such as polymer proportion, polymer viscosity, compression force and also the pH of dissolution medium on the in-vitro release of drug. Two viscosity grade of HPMC (15 K and 100 K) were used in the proportion of 50, 100, 150 and 200 mg per CR tablet. In-vitro release rate was characterized using various model dependent approaches and model independent dissolution parameters [T50% and T80% dissolution time, mean dissolution time (MDT), mean residence time (MRT), dissolution efficiency (DE)]. The statistical analysis was performed on all the model independent approaches using student t test and ANOVA. Results were found that as polymer concentration (50 mg to 200 mg) and viscosity (15 K to 100 K) increases, the MDT, MRT, T50% and T80% extended significantly. Drug release rate was found to be significantly different at different hardness. In-vivo human plasma concentration--time profile was predicted from in-vitro release data using convolution method. Predicted human pharmacokinetic parameters shows that the design CR formulation has capability to sustained the plasma drug level of milnacipran.
Department of Pharmacy, Industrial Research Laboratory, Birla Institute of Technology and Science , Pilani, Rajasthan , India.
Gautam
G
Singhvi
Abhishek
A
Shah
Nilesh
N
Yadav
Ranendra N
RN
Saha
D002626:Chemistry, Pharmaceutical / Q000379:methods; D003521:Cyclopropanes / Q000097:blood / Q000737:chemistry* / Q000493:pharmacokinetics; D003692:Delayed-Action Preparations / Q000737:chemistry / Q000493:pharmacokinetics; D006801:Humans; D006863:Hydrogen-Ion Concentration; D057927:Hydrophobic and Hydrophilic Interactions; D065347:Hypromellose Derivatives; D008747:Methylcellulose / Q000031:analogs & derivatives / Q000737:chemistry / Q000493:pharmacokinetics; D000078764:Milnacipran; D011108:Polymers / Q000737:chemistry / Q000493:pharmacokinetics; D012995:Solubility; D013607:Tablets / Q000737:chemistry* / Q000493:pharmacokinetics; D014783:Viscosity
D003521:Cyclopropanes; D003692:Delayed-Action Preparations; D011108:Polymers; D013607:Tablets; D065347:Hypromellose Derivatives; D008747:Methylcellulose; D000078764:Milnacipran